Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SEEL | US
0.12
11.88%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.13
1.01
1.25
1.01
Seelos Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapeutics for the treatment of central nervous system respiratory and other disorders. The company's lead programs are SLS-002 an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005 a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006 a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007 a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010 an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York New York.
View LessLow Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
244.4%1 month
307.8%3 months
228.3%6 months
184.6%0.00
-
15.10
-0.36
4.27
2.45
220.46
-
-27.71M
832.04K
832.04K
-
-834.84
-
11.90
-584.20
0.14
29.52
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.65
Range1M
4.38
Range3M
4.39
Rel. volume
0.00
Price X volume
28.34K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
International Stem Cell Corporation | ISCO | Biotechnology | 0.06 | 480.26K | 0.00% | n/a | 0.00% |
NexImmune Inc. Common Stock | NEXI | Biotechnology | 0.2514 | 350.62K | -23.82% | n/a | 0.00% |
Vaxxinity Inc. Class A Common Stock | VAXX | Biotechnology | 0.002 | 253.57K | 0.00% | n/a | 113.12% |
Navidea Biopharmaceuticals Inc | NAVB | Biotechnology | 0.001 | 100.08K | 0.00% | n/a | -38.49% |
U.S. Stem Cell Inc | USRM | Biotechnology | 0.0001 | 64.15K | 0.00% | n/a | -60.68% |
EFTR | EFTR | Biotechnology | 0.0012 | 5.64K | 0.00% | n/a | 2315.36% |
Calithera Biosciences Inc | CALA | Biotechnology | 0.001 | 4.87K | -50.00% | n/a | 8.17% |
XOMAP | XOMAP | Biotechnology | 26.24 | 0 | -0.23% | 26.27 | 121.93% |
XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock | XOMAO | Biotechnology | 25.5992 | 0 | 0.02% | 25.57 | 121.93% |
SABSW | SABSW | Biotechnology | 0.0534 | 0 | 8.54% | 0.17 | 11.58% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
No data |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 2.45 | 0.53 | Expensive |
Ent. to Revenue | 220.46 | 3,967.00 | Cheaper |
PE Ratio | 0.00 | 41.03 | Cheaper |
Price to Book | 15.10 | 15.55 | Par |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 228.34 | 72.80 | Riskier |
Debt to Equity | -0.36 | -1.23 | Expensive |
Debt to Assets | 4.27 | 0.25 | Expensive |
Market Cap | 832.04K | 3.66B | Emerging |